Synflorix Vaccine (Pneumococcal Polysaccharide Conjugate)

Product Details

Packaging Size 1 single dose 0.5 ml
Brand Synflorix
Manufacturer GSK
Prescription/Non prescription Prescription
Form Liquid
No. Of Dose Single
Packaging type Box
Package content 1 Vial (0.5ml)

$80

Safeguarding Babies: The Importance of Synflorix Vaccine against Pneumococcal Diseases

Pneumococcal Polysaccharide Conjugate vaccine, known as Synflorix, is essential for safeguarding babies against diseases like pneumonia, meningitis, ear, and blood infections. Administered intramuscularly by healthcare professionals, this vaccine prompts the body to produce antibodies, fortifying defense against these ailments.

 

Administration and Dosage

Synflorix Vaccine, offering protection against ten different strains of Streptococcus pneumoniae bacteria, is typically administered intramuscularly by a healthcare professional. The appropriate dosage, including considerations for babies, will be determined by your doctor based on your child’s needs.

 

Side Effects and Safety Measures

Common side effects may include loss of appetite, irritability, drowsiness, and fever, along with possible injection site reactions like pain, swelling, or redness. If these effects persist or worsen, consulting your doctor is advisable. It’s important to disclose any existing illnesses or medications your child is taking to ensure safety during vaccination.

 

Importance of Vaccination

Vaccination plays a pivotal role in preventing various pneumococcal diseases, especially in babies. Synflorix vaccine ensures protection against infections like pneumonia, meningitis, and blood, and ear infections, safeguarding the health of infants.

 

Development of Immunity

The vaccine stimulates immunity by inducing a mild infection that doesn’t cause illness but triggers the immune system to generate antibodies, offering protection against future infections.

 

Global Impact

In the developing world, young children and the older people bear the brunt of pneumococcal diseases. Approximately one million children succumbing to these ailments annually. Streptococcus pneumoniae, characterized by an encapsulated bacteria with a polysaccharide capsule, remains a significant cause of concern, with certain serotypes being more prevalent and virulent. The administration of the Synflorix vaccine substantially diminishes the risk of such infections, ensuring enhanced health outcomes for infants worldwide.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.